Viagra daily small dose may reduce the risk of colorectal cancer

Share This Post

Scientists report that a small daily dose of Viagra can significantly reduce the risk of colorectal cancer in animal models, which is the third leading cause of cancer death.

Dr. Darren D. Browning, a cancer researcher at the Georgia Cancer Center and the Department of Biochemistry and Molecular Biology, said that Viagra can reduce the formation of polyps in half. Polyps are an abnormal intestinal lining cell cluster and are often asymptomatic, but polyps have The possibility of becoming cancer.

Viagra can inhibit the naturally occurring enzyme PDE5 in colon cells and other decomposable circulating GMP tissues, so it can be used to reduce cell proliferation and improve cell differentiation, such as goblet cells secreting protective mucus. The study found that targeting circulating GMP signaling seems to be a good prevention strategy for high-risk patients.

The study found that placing Viagra in the drinking water of mice reduced polyps in the mouse model, and the mice had genetic mutations in adenomatous polyposis coli (APC). Like these mice, people with  mutations in the APC gene can develop into hundreds or thousands of polyps in the colon and rectum, and ultimately eventually cause colorectal cancer. At the same time, giving Viagra to young mice can reduce the number of tumors in these animals by half.

He pointed out that Viagra has been on the market for many years and is known for its ability to relax smooth muscle cells around blood vessels. It is used in people with multiple doses and age groups, from patients with premature pulmonary hypertension to elderly people with erectile dysfunction. Dr. Browning said that the next step should include clinical trials of drugs in people at high risk for colorectal cancer, such as those with a strong family history, multiple polyps, and chronic intestinal inflammation such as colitis. If the test achieves gratifying results, Viagra will refresh the indications for cancer prevention.

Website |  + posts

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
Cancer

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor

The FDA approved vimseltinib for symptomatic tenosynovial giant cell tumor (TGCT) in patients who cannot be treated with surgery. The oral CSF1R inhibitor blocks tumor growth and alleviates symptoms, providing a surgery-free way to control TGCT. The approval is based on clinical trial evidence of substantial tumor shrinkage and symptom relief. The approval is a significant step forward in TGCT treatment, enhancing the quality of life for these patients.

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma
Blood cancer

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma

The FDA approved brentuximab vedotin in combination with lenalidomide and rituximab to treat relapsed or refractory large B-cell lymphoma (LBCL). The combination represents a new option for treatment after failure of initial therapies. The approval follows the presentation of data from clinical trials showing that this combination improved patient outcomes. This combination is a new strategy in the management of LBCL and provides a greater number of available treatments for those with few choices.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟